Zenith Epigenetics Announces Appointment to Board of Directors and Provides Clinical Update
Retrieved on:
Monday, January 31, 2022
CEO, Disorder, United Nations, Pembrolizumab, Patient, Ipilimumab, MCRPC, NASDAQ, NUT, University, Audit committee, Immunology, Ovarian cancer, PARP, Biotechnology, Entinostat, Board of directors, Research, BET, Board, NASA, US, Triple-negative breast cancer, Cancer, TSX, Alberta Stock Exchange, Private sector, Colorado State University, GLOBE, Canadian Space Agency, Doctor of Philosophy, Merck, ASCO, US FDA, CDNX, Therapy, Nivolumab, University of California, San Francisco Fetal Treatment Center, First Nations in Ontario, Director, Lymphoma, Management, Pharmaceutical industry, Microbiology, Zenith
CALGARY, Alberta, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Zenith Capital Corp. (Zenith or the Company) today announced the appointment of Dr. Brad Thompson, PhD, to its board of directors.
Key Points:
- CALGARY, Alberta, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Zenith Capital Corp. (Zenith or the Company) today announced the appointment of Dr. Brad Thompson, PhD, to its board of directors.
- I am thrilled to be joining Zenith at such an exciting time in the clinical development of its lead compound ZEN-3694, said Dr. Thompson.
- Dr. Thompsons appointment coincides with Dr. Eldon Smith having stepped down from the Board of Directors, effective today.
- Zenith Epigenetics is developing various novel combinations of BET inhibitors with other targeted agents.